Betsy McCollum
A5045364272- Schizophrenia research and treatment
- Pharmacological Effects and Toxicity Studies
- Bipolar Disorder and Treatment
- Pharmaceutical studies and practices
- Pharmacogenetics and Drug Metabolism
- Electroconvulsive Therapy Studies
- Parkinson's Disease and Spinal Disorders
- Treatment of Major Depression
- Epilepsy research and treatment
- Glycogen Storage Diseases and Myoclonus
- Diet and metabolism studies
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune Neurological Disorders and Treatments
- HIV/AIDS drug development and treatment
- Pharmaceutical Practices and Patient Outcomes
- Pharmacovigilance and Adverse Drug Reactions
- Tuberculosis Research and Epidemiology
Eastern State Hospital
2015-2025
University of Kentucky
2015-2019
Zucker Hillside Hospital
2019
Feinstein Institute for Medical Research
2019
Northwell Health
2019
Abstract This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that is the third most toxic in United States (US), it produces four times higher pneumonia mortality than agranulocytosis or myocarditis. For trough steady-state serum concentrations, therapeutic reference range narrow, from 350 to 600 ng/mL with potential for toxicity ADRs as concentrations increase....
Valproic acid (VPA) can autoinduce its own metabolism. Cases requiring VPA doses >4000 mg/day to obtain therapeutic plasma concentrations, such as these 3 cases, have never been published. Case 1 received for seizures and schizophrenia had >50 concentrations in 4 years. A high dose of 5,250 concentrate was prescribed years but this led an intoxication when switched the enterocoated divalproex sodium formulation, a normal 2000 mg/day. metabolic capacity significantly higher (t = -9.6; df 6.3,...